Mabthera: Clinical Trials

258 trials of Mabthera, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

113 completed, 40 terminated, 33 active not recruiting, 33 recruiting. 258 Phase 2, 58 Phase 1, 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2258Completed 113, Terminated 40, Active not recruiting 33, Recruiting 33, Unknown 21, Withdrawn 14, Suspended 3, Not yet recruiting 1
Phase 158Completed 27, Terminated 12, Active not recruiting 6, Unknown 5, Recruiting 4, Withdrawn 3, Suspended 1
Phase 38Completed 4, Active not recruiting 2, Recruiting 1, Unknown 1

Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera

Trials (filtered) newest first · largest first

All 258 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1 / Phase 2RecruitingCity of Hope Medical Center582026-12-212026-10-22
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Phase 2RecruitingCity of Hope Medical Center352026-10-232026-10-29
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Phase 2RecruitingUniversity of Washington302026-10-092026-10-15
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma
Phase 2RecruitingAIDS Malignancy Consortium432026-09-162026-11-17
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Phase 2RecruitingCity of Hope Medical Center432026-07-272026-08-28
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Phase 2SuspendedUniversity of Washington302026-05-082026-09-29
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Chidamide, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2RecruitingOu Bai, MD/PHD502026-04-302026-03-25
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 2RecruitingUniversity of Washington332026-03-302026-08-13
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Phase 2RecruitingUniversity of Washington182025-12-072026-10-21
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Phase 2RecruitingCity of Hope Medical Center532025-10-102026-10-13
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 2RecruitingUniversity of California, Davis252025-07-312026-06-30
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 2RecruitingFred Hutchinson Cancer Center302025-06-022026-10-30
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma
Phase 2RecruitingChristine Ryan602025-04-222026-02-20
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2RecruitingMayo Clinic412025-04-022026-10-20
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia
Phase 1 / Phase 2RecruitingJennifer R. Brown, MD, PhD642025-03-192026-02-11
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab), Placebo - Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Phase 2RecruitingPolTREG S.A.1502025-03-122026-07-17
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma
Phase 2RecruitingCity of Hope Medical Center272025-01-222026-03-13
Epco, Zanu, Ritux for R/R FL or MZL
Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma
Phase 2RecruitingReid Merryman, MD712025-01-212026-09-25

Showing 20 of 258. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (69)  ·  Lymphoma, Mantle-Cell (56)  ·  Lymphoma, Follicular (52)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (44)  ·  Lymphoma, Non-Hodgkin (40)  ·  Burkitt Lymphoma (38)  ·  Lymphoma, B-Cell, Marginal Zone (36)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (28)  ·  Waldenstrom Macroglobulinemia (26)  ·  Lymphoma (23)  ·  Lymphoma, B-Cell (17)  ·  Hodgkin Disease (15)  ·  Lymphoma, Large-Cell, Immunoblastic (14)  ·  Recurrence (11)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9)

Sponsors

M.D. Anderson Cancer Center (44)  ·  National Cancer Institute (NCI) (31)  ·  University of Washington (12)  ·  City of Hope Medical Center (11)  ·  Fred Hutchinson Cancer Center (10)  ·  Mayo Clinic (6)  ·  Hoffmann-La Roche (4)  ·  Northwestern University (4)  ·  Academic and Community Cancer Research United (3)  ·  Arbeitsgemeinschaft medikamentoese Tumortherapie (3)  ·  Fudan University (3)  ·  Stanford University (3)  ·  The Lymphoma Academic Research Organisation (3)  ·  Asan Medical Center (2)  ·  Case Comprehensive Cancer Center (2)

Countries

United States (182)  ·  Italy (18)  ·  United Kingdom (18)  ·  France (12)  ·  Germany (11)  ·  China (10)  ·  South Korea (9)  ·  Australia (8)  ·  Belgium (7)  ·  Canada (7)  ·  Spain (6)  ·  Austria (5)  ·  Mexico (5)  ·  Poland (4)  ·  Brazil (3)

Top investigators

Elias Jabbour (7)  ·  Ajay Gopal (4)  ·  Thomas Witzig (3)  ·  Ye Guo, MD (3)  ·  David Gomez-Almaguer, MD (2)  ·  David Maloney (2)  ·  Deepa Jagadeesh, MD, MPH (2)  ·  Edmund Kwok Ming LI, MD (2)  ·  Farhad Ravandi-Kashani (2)  ·  Geoffrey Shouse (2)  ·  Grzegorz S Nowakowski (2)  ·  Issa F Khouri (2)  ·  Issa Khouri (2)

Results publications

PMID 39319495, PMID 34515338, PMID 34797699, PMID 35952327, PMID 39513526, PMID 41671463, PMID 12907446, PMID 17687130, PMID 20023215, PMID 20039397, PMID 20039413, PMID 20131246, PMID 20841509, PMID 21325353, PMID 21440503, PMID 21478218, PMID 21508413, PMID 21821712, PMID 22535574, PMID 22734071, PMID 23401442, PMID 23547837, PMID 23592273, PMID 23753028, PMID 23753030, PMID 23799873, PMID 23834234, PMID 24297953, PMID 24458437, PMID 24516013, PMID 24638012, PMID 25304612, PMID 25343233, PMID 25439689, PMID 26065651, PMID 26248505, PMID 26250576, PMID 26378033, PMID 26432046, PMID 26640039, PMID 26643449, PMID 26844479, PMID 27018242, PMID 27118452, PMID 27132696, PMID 27530379, PMID 27536708, PMID 28314744, PMID 28314788, PMID 28637670

NIH funding

P30CA015704 (10), P30CA033572 (9), P30CA016672 (7), P30CA015083 (5), U10CA180821 (5), 2009 (4), U10CA021115 (4), U10CA031946 (4), P30CA060553 (3), U10CA025224 (3), U10CA032102 (3), U10CA180820 (3), U10CA180888 (3), 2015 (2), 2016 (2)